Skip to main content

Biocartis, AstraZeneca Partner on European Lung Cancer Biomarker Study

NEW YORK (GenomeWeb) – Biocartis announced today that it has partnered with AstraZeneca on a European study designed to obtain faster lung cancer molecular diagnostics results.

As part of the agreement, the firms will begin a prospective lung cancer study using Biocartis' Idylla EGFR mutation test in European countries including Belgium, France, Germany, and Italy.

Biocartis highlighted that the study will demonstrate how Idylla, a fully automated real-time PCR-based testing platform, can overcome the complexity and long turnaround time of molecular testing for lung cancer patients by delivering faster and accurate biomarker results.

Financial details regarding the agreement and addition information about the prospective clinical study were not disclosed.

"With this prospective study, we expect once again to demonstrate the positive impact of delivering highly accurate biomarker results in a fast and easy way," Biocartis CEO Herman Verrelst said in a statement.

Biocartis said earlier this month that it is adjusting its guidance for 2018, increasing its projection for new instrument placements and narrowing expectations for cartridge volume. The firm also presented lung adenocarcinoma data on the EGFR assay last month during a presentation at the Association for Molecular Pathology annual meeting.